All In Biotech

Investigational drug · Phase 3

Centhaquine

Also called: PMZ-2010

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Acute Respiratory Distress Syndrome (ARDS), Hypovolemic Shock.

Phase 3

Last checked: Nov 20, 2026Latest source record: Sep 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

2

2 still active

All registered trials

6

Any phase or sponsor naming "Centhaquine"

First trial start

2027

Feb 2027

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Centhaquine", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Acute Respiratory Distress Syndrome (ARDS)
  • Hypovolemic Shock

Approved drugs for the same conditions: Rare and genetic disease

Largest trials

Live from ClinicalTrials.gov: studies naming "Centhaquine" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 14 on PubMed

Also in development for Acute Respiratory Distress Syndrome (ARDS)

  • STSA-1002Phase 32 trials

    Staidson (Beijing) Biopharmaceuticals Co., Ltd · Acute Respiratory Distress Syndrome (ARDS), Acute Respiratory Distress Syndrome

  • paridiprubartPhase 22 trials

    PPD Development, LP · Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome)

  • vilobelimabPhase 22 trials

    PPD Development, LP · Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome)

  • ALT-100Phase 21 trial

    Aqualung Therapeutics Corp. · Acute Respiratory Distress Syndrome (ARDS)

  • TISA-818-InjPhase 21 trial

    EnliTISA (Shanghai) Pharmaceutical Co., Ltd. · Acute Respiratory Distress Syndrome (ARDS)

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.